Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2006

View Archived Issues

BIM-28125: new ghrelin agonist improves glucocorticosteroid catabolic effects

FG-3019 has multiple effects in pancreatic cancer models

Clearance sought for study of oral interferon alpha in IPF

Ricerca BioSciences, new development partner for PhytoMedical's BDC-03

Athenagen and Zapaq to merge

TAK-491 for hypertension enters phase II

Portola studies oral Factor Xa inhibitor in knee replacement surgery patients

Antiarrhythmic efficacy and tolerability of the dual potassium/sodium channel blocker RSD-1235

Neose updates NE-180 progress

Xencor completes bridge financing

Alfacell forms collaboration for next-generation targeted therapies for cancer

Procter & Gamble and ARYx form alliance for GI drug ATI-7505

Novel antiinfective agents disclosed in recent patent literature

Curis and Genentech halt phase I basal cell carcinoma study

Phase I study of PhytoSel to lower side effects of chemotherapeutic drugs

EMEA clears Kamada's phase I plans for alpha-1 proteinase inhibitor

CB-7630 begins U.S. phase I study for advanced prostate cancer

Recent patents describe new therapeutic agents for diabetes

Eisai and Teva to end rasagiline collaboration agreement

Zhejiang University report on new antitumor agent targeted for cervical cancer

Banyu studies Gardasil in Japan

New possible treatments for metabolic disorders described in recent patents

Preclinical thrombolytic activity of HTU-PA shown in rat, hamster, rabbit and dog models

FDA approves Atripla, first once-daily single tablet regimen for HIV

Novel DHEA analogue shows antiarrhythmic potential without inducing QT prolongation

CJC-1295 normalizes body weight and length parameters in a mouse model of GH deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...